Source: European Investment Bank
EUR 20 million EIB loan will be used to accelerate research and development of Nightingale’s blood analysis technology.
Loan backed by European Fund for Strategic Investments, part of the Juncker Plan.
Nightingale Health, the Finnish innovator of an internationally recognized blood analysis technology for chronic disease prevention, today signed a EUR 20 million loan transaction with the European Investment Bank (EIB), guaranteed by the European Fund for Strategic Investments (EFSI), a key element of the Investment Plan for Europe, also known as the Juncker Plan. The loan will be used to further accelerate the research and development of Nightingale’s blood analysis technology, facilitating better prediction and prevention for chronic diseases.
EIB Vice-President Alexander Stubb, responsible for innovation, said: “Chronic diseases are a nightmare, not only for those who suffer from them, but also for those trying to cure them. The EIB is committed to supporting companies like Nightingale that can realistically make a big impact and improve the health of EU citizens. The support of the Investment Plan for Europe is particularly valuable here, and the operation is fully aligned with the objective of supporting high-skilled employment opportunities. This will also enhance Europe’s position as a major leader in medical innovation.”
European Commission Vice-President Jyrki Katainen, responsible for jobs, growth, investment and competitiveness, said: “Europe invests heavily in education and science as we believe that putting a strategic effort into these areas can reap huge benefits. This commitment has resulted in Europe’s position today as a world leader in cutting edge medical research. We are delighted that the Investment Plan for Europe is fostering the development of Nightingale’s technology which has the potential to add significant value to European healthcare.
Nightingale CEO and Founder Teemu Suna said: “Nightingale wants to create a world where healthcare keeps people healthy throughout their lifetimes, not just whenever they get sick. When we founded Nightingale in 2013, we wanted to bring together innovations from biotechnology, medicine and computer sciences to build a different type of healthcare – one where everyone is given a chance to live a healthier life. Today’s announcement provides Nightingale with the funding needed to take our vision for personalized medicine into European healthcare. By supplying physicians with accurate chronic disease risk prediction for their patients, we will empower people to better understand their own health status and take actions to reduce their risk. Not only will this transform how we treat common diseases such as diabetes and heart disease, but it will also significantly reduce the current economic burden on healthcare systems and workforces.”
The growing burden of chronic disease poses a significant threat to citizens’ wellbeing. It is also estimated that 70-80% of all healthcare costs in the EU are chronic disease-related, accounting to approximately EUR 700 billion(1). Nightingale’s innovative blood analysis technology can detect early signs of a large number of these diseases, improving the assessment of a person’s future risk of developing heart disease and type 2 diabetes. By helping physicians and patients to better understand an individual’s chronic disease risk, effective interventions such as medications and lifestyle changes can be taken to slow and prevent disease progression.
The EUR 20 million loan from the EIB represents another major step forward towards integrating Nightingale’s technology in European healthcare. Already used widely in public health research, the company’s goal is to achieve full clinical integration for its technology by replacing conventional biomarker tests for chronic diseases (e.g. cholesterol tests). By further accelerating the regulatory approval process through rigorous scientific evidence generation, the company aims to realise the promise of precision medicine. Nightingale has already received CE marking for its blood analysis technology in 2017, enabling clinical use of its technology in Europe, and its Quality Management System is certified to EN ISO 13485:2012. Nightingale will match the EIB’s loan, altogether resulting in EUR 40 million in total investment that will be used within the next 3-5 years to further advance Nightingale’s R&D and scientific evidence generation.
Nightingale Health is the Finnish innovator of an award winning blood analysis technology. By measuring the comprehensive health state from a person using a single blood sample, Nightingale equips biomedical researchers with insights into the effects of lifestyle factors and future disease risk, accelerating breakthroughs in chronic disease prevention. The company is investing and working towards integrating its technology into clinical practice to bring about precision medicine – empowering patients to follow up on their own well-being and take proactive steps to stay healthy.